Background {#Sec1}
==========

Pain is known as a major public health threat not only because it underlies almost every illness but also because it has become an illness by himself. It is therefore one of the leading causes of medical consultation \[[@CR1]\], with enormous socio-economic and physiological deleterious impacts. Therefore, there is a high need to properly handle this ailment especially at its chronic stage. Huge progress has been made in recent years in order to first understand the pathology and secondly to master the therapeutic aspects and treatment. For the last purpose, a large number of therapeutics molecules like opioids, non-steroidal and steroidal analgesics have been developed. But existing therapeutics have some disadvantages such as their inefficacy, the resistance of some pathologies and the side effects, especially gastrointestinal, hepatic or renal toxicity. For instance, patients with severe inflammatory diseases respond poorly to conventional doses of corticosteroids \[[@CR2], [@CR3]\]. One of the exciting strategies to overcome these problems is to search for new and better drugs with minimal adverse effects. An important field of investigation to discover new therapeutic molecules that can treat more efficiently pain is that of secondary metabolites present in medicinal plants. In fact phytopharmacological research has brought substantial contribution to drug innovation. In addition, chemical structural modification of molecules has been shown to strongly modify the biological activity of initial compounds. In fact, the analgesic activity of a good number of chemical has been improved by their structural modification \[[@CR4]--[@CR6]\].

Triterpenes constitute a class of secondary metabolites that have shown potent analgesic and anti-inflammatory activities \[[@CR7]--[@CR9]\], one of the subclass being cycloartanes. The lasts molecules are secondary metabolites belonging to the class of tetracyclic triterpenes and are synthesized by many plant species. Cycloartanes possess various biological activities including anti-tumour, anti-virus, antibacterial, anti-inflammatory, analgesic or antioxidant activities \[[@CR10], [@CR11]\]. They therefore, offer an alternative in the treatment of pain.

Ayatollahi et al. \[[@CR12]\] showed that cycloartanes are able to deactivate protein kinase C (PKC) and that this effect could be attributed to the presence of hydroxyl group in their molecular structures. Knowing the pivotal role that PKC plays in the transduction of pain \[[@CR13], [@CR14]\], we hypothesized that cycloartanes may possess good analgesic activity related to the presence of hydroxyl group.

The present study evaluates the analgesic and anti-inflammatory activities of three cycloartane glycosides, named pallidioside A (OP~3~), pallidioside B (OP~5~) and pallidioside C (OP~6~) isolated from the leaves of *Oxyanthus pallidus*, a plant extensively used in the West region of Cameroon as analgesic. In attempt to determine the importance of the glycoside moiety and the hydroxyl group in the biological activity of these compounds, the effects of their respective aglycone (AOP~1~, AOP~2~, AOP~3)~ and acetylated (HOP~1,~ HOP~2~, HOP~3~) derivatives were also evaluated.

Methods {#Sec2}
=======

Animal {#Sec3}
------

Male and female rats of the Wistar strain aged 3 months and weighing between 180 and 200 g and Swiss mice of both sexes, aged 3 months and weighing between 20 and 30 g were used in this study. These animals were bred in the animal house of the Laboratory of Animal Physiology and Phytopharmacology of the University of Dschang under a 12-h light/dark cycle with free access to standard commercialized rodent diet and water. The number of animals used was the minimum possible to determine consistent effects of the drug treatments (See figures). All protocols were submitted and approved by the local Ethics Committee "The Animal Ethics Committee of the University of Dschang" and conformed to the guidelines for the study of pain in awake animals established by the International Association for the Study of Pain.

Plant collection and extraction {#Sec4}
-------------------------------

### Collection and isolation of major compounds {#Sec5}

*Oxyanthus pallidus* materials were harvested in November in Dschang in the Western region of Cameroon. The plant was identified at the National Herbarium of Cameroon in Yaounde by Mr. Victor Nana, in comparison to an existing Voucher specimen n^o^ 7335/SFR/CAM. The leaves were subsequently dried at room temperature and then crushed. The resulting powder was extracted by soaking in methanol for 24 h. After filtration and evaporation at 70 °C under reduced pressure, the extract obtained was subsequently subjected to repeated column chromatography silica gel, which allowed to isolate and identify the three main compounds pallidiosides A (OP~3~), pallidiosides B (OP~5~) and pallidiosides C (OP~6~) as previously described \[[@CR15]\].

### Preparation of aglycone derivatives {#Sec6}

One point five gram of each compound (OP~3~, OP~5~ and OP~6~) was individually refluxed in methanol/H~2~SO~4~ 10 % (25 ml) at room temperature for 48 h. Reaction mixture was neutralized by sodium hydroxide solution (6 N) and extracted with CHCl~3~ (3 × 10 ml). Each organic phase was concentrated under vacuum to give residues (560, 530 and 540 mg respectively) which were separately subjected to CC over silica gel with hexane/AcOEt (1:1) as the eluent to yield AOP~1~, AOP~2~ and AOP~3~ compounds (350, 335 and 340 mg respectively).

### Preparation of acetylated derivatives {#Sec7}

Two hundred and fifty milligrams of each compound (OP~3~, OP~5~ and OP~6~) were individually acetylated with Ac~2~O--pyridine (2:1) v/v at room temperature for 24 h, and each of the reaction mixture was purified over silica gel column, eluted with the hex-EtOAc (50 %) mixture to give the corresponding acetylated derivatives HOP~1~, HOP~2~ and HOP~3~ (270, 280 and 285 mg respectively).

Pharmacological tests {#Sec8}
---------------------

### Spontaneous pain induced by formalin in mice {#Sec9}

This experiment followed the procedure previously described \[[@CR16]\]. Animals were orally treated (gavage) with the mixture of the three cycloartanes (5, 10 and 20 mg/kg), individual isolated compounds (5 mg/kg) or derivatives (5 mg/kg). Diclofenac given orally at 5 mg/kg was used as positive control while the negative control group received 0.9 % NaCl solution. All the oral administered substances were given at equivalent volume of 0.5 ml/30 g body weight. One hour after administration of different substances, pain was induced by injecting 20 μL of formalin (2.5 % in saline) under the aponeurosis of the dorsal surface of the right hind paw of each animal. They were individually observed and pain evidenced by licking, flinching or biting the injected paw was quantified using an electronic timer, in two periods. The first period consisted of the first 5 min indicating neurogenic pain and second period (15th to 45th minute) corresponding to the tonic inflammatory pain.

### Mechanical hyperalgesia and inflammation induced by formalin in rats {#Sec10}

In an attempt to evaluate the time-dependent analgesic and anti-inflammatory effects, OP~5~ and OP~6~ were tested acutely in formalin-induced pain. The effect of 10 days repeated administration of OP~5~ (2.5 and 5 mg/kg/day as a single bolus) was also tested. NaCl 0.9 % and diclofenac were respectively used for negative and positive controls. One hour after oral administration of various substances, pain and inflammation were induced by injecting 0.1 ml of a 2 % formalin solution, under the left hind paw of each rat \[[@CR17]\]. Ugo Basile analgesy meter no. 372157 and the caliper were used to measure the response threshold of each animal to mechanical pain and the paw diameter, respectively. The response threshold of the animal to mechanical pain was reported before treatment and 1, 2, 4, 6, 8 and 24 h post injection for the first day and once a day for ten days. The diameter of the injected paw was measured before treatment and 3, 5, 7 and 24 h post injection for the first day and then once a day for ten days. For repeated treatments, drugs were administered once a day, after collection of data. At the end of the experiment, the antioxidant, hepatotoxic and ulcerogenic effects of chronic administration of OP~5~ were examined. On this purpose, animals were sacrificed on day 11. Blood, kidney and liver samples were collected. Serum was separated for ALAT and ASAT assays. Kidney and liver were homogenized in Tris buffer and centrifuged. The supernatant was used to assay nitric oxide, malondialdehyde, superoxide dismutase, catalase and glutathione. Immediately after blood, liver and kidney collection, the stomach was carefully dissected out and opens along the great curvature. The mucus weight and ulceration index were estimated as previously described \[[@CR18]\].

Biochemical analysis {#Sec11}
--------------------

To assess whether different treatments could induce liver damage, enzymatic activities of aspartate aminotrasferase (AST) and alanine aminotrasferase (ALT) were measured in serum following the commercial kit (Immesco) procedure. SOD was evaluated based on its ability to inhibit or retard the autoxidation of adrenaline to adrenochrome in basic medium \[[@CR19]\]. To assess whether the tested compound could inhibit lipid peroxidation, the amount of malondialdehyde was assayed in homogenates of liver and kidney. The protocol followed was as previously described by Ohkawa et al. \[[@CR20]\]. Glutathione concentration and catalase activity in tissues homogenates were measured according to the methods described by Dimo et al. \[[@CR21]\]. NO content in the homogenates of kidney and liver was measured, using Fiddler's method \[[@CR22]\].

Statistical analysis {#Sec12}
--------------------

Results are expressed as Mean ± SEM (Standard Error of the Mean). One-way ANOVA followed by the Turkey's post test was used to compare the averages for the various groups in the antinociceptive tests in mice and in biochemical analysis. Two-way ANOVA followed by Bonferroni post-test was used to compare different groups in the antihyperalgesic and the inflammatory tests. These analyses were performed with the aid of Graph Pad Prism software version 5.0.

Results {#Sec13}
=======

Cycloartanes {#Sec14}
------------

The individual main compounds are all characterized by the same basic structure and differ only on carbon 24. This carbon atom, bearing one *α*-OH in OP~5~ and one *β*-OH in OP~6~ respectively, was oxidized in ketone in molecule OP~3~ (Fig. [1](#Fig1){ref-type="fig"}). ^1^H and ^13^C data of these compounds were previously described by Tigoufack et al. \[[@CR15]\].Fig. 1Structures of the main cycloartanes (pallidioside A: OP~3~, pallidioside B: OP~5~ and pallidioside C: OP~6~) isolates from the leaves of *Oxyanthus pallidus*

The aglycons derivatives generally have the same basic structure as the main compound from which they derived except the fact that, carbon atom C-7 which was linked to a glucosyl moiety in each precursor, was now linked to a *β*-OH group as indicated in Fig. [2](#Fig2){ref-type="fig"}.Fig. 2Structures of respective aglycones (AOP~1~, AOP~2~, AOP~3~) and acetylated (HOP~1~, HOP~2~ and HOP~3~) derivatives of OP~3~, OP~5~ and OP~6~

AOP~1~ was obtained as a white powder. \[α\]D~23~ = + 85 (CH~3~OH, *c* = 0.92); IR (NaCl) ν~max~ (cm^−1^): 3375 (OH), 1703 (C = O), 1246 (C-O), ^1^H and ^13^C NMR data see Table [1](#Tab1){ref-type="table"}. HR-TOFESIMS *m/z*: 513.3717 \[M + Na\]^+^ (calcd. For C~30~H~50~O~5~Na, 513.3712).Table 1^1^H (600 MHz, MeOD) and ^13^C (150 MHz, MeOD) data of AOP~1~, AOP~2~ and AOP~3~PositionsAOP~1~AOP~2~AOP~3~δ~C~δ~H~ *(mult, J(Hz)*δ~C~δ~H~ (*mult, J(Hz*)δ~C~δ~H~ (*mult, J (Hz)*131.51.33 (1H, m, Hβ), 1.61 (1H, m, Hα)31.31.33 (1H, m, Hβ), 1.60 (1H, m, Hα)31.31.33 (1H, m, Hβ), 1.62 (1H, m, Hα)230.51.64 (1H, m, Hα), 1.73 (1H, m, Hβ)29.41.64 (1H, m, Hα), 1.73 (1H, m, Hβ)29.41.63 (1H, m, Hα), 1.72 (1H, m, Hβ)379.13.17 (dd, 4.6, 10.1)77.73.24 (dd, 4.4, 11.1)78.03.17 (dd, 4.5, 10.1)441.239.8/39.8/545.61.51 (dd, 3.7, 13.1)45.71.52 (dd, 3.9, 13.1)45.71.51 (dd, 3.8, 12.1)629.31.04 (1H, m, Hα), 1.74 (1H, m, Hβ)30.71.04 (1H, m, Hα), 1.74 (1H, m, Hβ)30.71.03, (1H, m, Hα), 1.74 (1H, m, Hβ)770.13.50 ddd (4,0, 7.1, 12.6)70.03.50 ddd (4,0, 7.1, 12.7)70.03.50 (ddd, 4.0, 9.4, 13.3)854.41.72 (1H, d, 7.0)54 .21.71 (1H, d, 6.0)54.21.72 (1H, d, 6.0)926.626.5/26.5/1019.719.6/19.7/1126.01.31 (1H, m, Hα), 1.90 (1H, m, Hβ)26.01.31 (1H, m, Hα), 1.92 (1H, m, Hβ)26.01.30 (1H, m, Hα), 1.92 (1H, m, Hβ)1232.81.61 (1H, m, Hα), 1.68 (1H, m, Hβ)32.41.63 (1H, m, Hα), 1.69 (1H, m, Hβ)32.31.62 (1H, m, Hα), 1.68 (1H, m, Hβ)1345.345.4/45.4/1446.046.0/46.0/1548.81.64 (1H, dd, 5.2, 7.5, Hβ), 2.25 (1H, dd, 5.2 7.5, Hα)48.81.66 (1H, dd, 5.2, 7.6, Hβ), 2.25 (1H, dd, 5.2, 7.6, Hα)48.81.67 (1H, dd, 5.2, 7.7, Hβ), 2.25 (1H, dd, 5.2, 7.7, Hα)1672.14.43 (1H, ddd, 5.2, 7.5, 7.8)72.14.44 (1H, ddd, 5.2, 7.6, 7.9)72.04.43 (1H, ddd, 5.2, 7.6, 7.9)1755.81.63 (1H, dd, 7.8, 12.3)55.91.64 (1H, dd, 7.9, 12.4)55.81.63 (1H, dd, 7.9, 12.4)1817.21.20 (3H, s)17.31.22 (3H, s)17.21.21 (3H, s)1927.90.19 (1H, d, 4.0, Hα), 0.87 (1H, d, 4.0, Hβ)27.90.19 (1H, d, 4.0, Hα), 0.85 (1H, d, 4.0, Hβ)27.90.75 (1H, d, 4.0, Hα), 0.86 (1H, d, 4.0, Hβ)2030.11.81 (1H, m)28.41.92 (1H, m)28.51.82 (1H, m)2117.50.99 (1H, d, 7.6)17.60.99 (1H, d, 7.6)17.51.00 (1H, d, 7.6)2231.11.26 (1H, m, Hα),, 1.82 (1H, m, Hβ)32.31.24 (1H, m, Hα), 1.82 (1H, m, Hβ)32.51.22(1H, m, Hα),, 1.92(1H, m, Hβ)2328.31.63 (1H, m, Hα), 1.70 (1H, m, Hβ)27.01.63 (1H, m, Hα), 1.72 (1H, m, Hβ)28.01.62 (1H, m, Hα), 1.72 (1H, m, Hβ)24218.977.03.40 (1H, dd, 5.1, 12.0)79.33.25 (1H, dd, 4.9, 11..3)2577.872.4/72.4/2626.81.19 (3H, s)24.01.19 (3H, s)24.31.19 (3H, s)2726.81.17 (3H, s)23.91.17 (3H, s)23.41.16 (3H, s)2826.00.98 (3H, s)24.60.98 (3H, s)24.60.98 (3H, s)2913.20.86 (3H, s)13.10.84 (3H, s)14.90.86 (3H, s)3018.50.97 (3H, s)18.40.97 (3H, s)18.40.97 (3H, s)

AOP~2~ was obtained as a white powder. \[α\]D~23~ = + 58.6 (CH~3~OH, *c* = 0.89); IR (NaCl) ν~max~ (cm^−1^): 3465 (OH), 1249 (C-O), ^1^H and ^13^C data, see Table [1](#Tab1){ref-type="table"}; HR-TOFESIMS *m/z*: 515.3719 \[M + Na\]^+^ (calcd. For C~30~H~52~O~5~Na, 515.3712).

AOP~3~ was obtained as a white powder. \[α\]D~23~ = + 34.2 (CH~3~OH, *c* = 1.20); IR (NaCl) ν~max~ (cm^−1^): 3477 (OH), 1250 (C-O), ^1^H and ^13^C data, see Table [1](#Tab1){ref-type="table"}; HR-TOFESIMS *m/z*: 515.3719 \[M + Na\]^+^ (calcd. For C~30~H~52~O~5~Na, 515.3712).

The acetylated derivatives generally have the same basic structure as the main compound from which they derived except the fact that all primary and secondary hydroxyl groups were acetylated as showed in Fig. [2](#Fig2){ref-type="fig"}.

HOP~1~ was obtained as a white powder. \[α\]D~23~ = + 18.2 (CH~3~OH, *c* = 0.482 × 10^−2^); IR (NaCl) ν~max~ (cm^−1^): 3450 (OH), 1249 (C-O), 1715 (C = O). ^1^H and ^13^C data, see Table [2](#Tab2){ref-type="table"}.Table 2^1^H (500 MHz, MeOD) and ^13^C (150 MHz, MeOD) data of HOP~1~, HOP~2~ and HOP~3~PositionsHOP~1~HOP~2~HOP~3~δ~C~δ~H~ *(mult, J(Hz)*δ~C~δ~H~ (*mult, J(Hz*)δ~C~δ~H~ (*mult, J (Hz)*130.41.40 (1H, m, Hβ), 1.60 (1H, m, Hα)29.11.62 (1H, m, Hβ), 1.72 (1H, m, Hα)29.11.62 (1H, m, Hβ), 1.72 (1H, m, Hα)229.11.62 (1H, m, Hα), 1.73 (1H, m, Hβ)27.01.43 (1H, m, Hα), 1.62 (1H, m, Hβ)27.01.43 (1H, m, Hα), 1.62 (1H, m, Hβ)377.83.22 (dd, 4.4, 11.1)77.83.23 (dd, 4.2, 10.9)77.83.23 (dd, 4.2, 10.9)439.8/39.8/39.8/544.31.42 (dd, 3.9, 13.3)44.21.45 (dd, 3.9, 13.1)44.21.45 (dd, 3.9, 13.1)628.11.08 (1H, m, Hα), 2.13 (1H, m, Hβ)28.11.10 (1H, m, Hα), 2.13 (1H, m, Hβ)28.11.10 (1H, m, Hα), 2.13 (1H, m, Hβ)780.03.63 (ddd (4,0, 7.63, 12.6)80.03.63 (ddd (4,0, 7.1, 12.7)80.03.63 (ddd (4,0, 7.1, 12.7)850.22.09 (1H, d, 7.63)50.02.11 (1H, d, 6.0)50.02.11 (1H, d, 6.0)920.1/20.2/20.2/1026.4/26.4/26.4/1126.51.33 (1H, m, Hα), 1.90 (1H, m, Hβ)30.31.42 (1H, m, Hα), 1.62 (1H, m, Hβ)30.31.42 (1H, m, Hα), 1.62 (1H, m, Hβ)1232.31.60 (1H, m, Hα), 1.68 (1H, m, Hβ)32.41.60 (1H, m, Hα), 1.69 (1H, m, Hβ)32.41.60 (1H, m, Hα), 1.69 (1H, m, Hβ)1346.4/46.4/46.4/1445.3/45.3/45.3/1546.61.64 (1H, dd, 5.0, 7.5, Hβ), 2.33 (1H, dd, 5.0 7.5, Hα)46.41.63 (1H, dd, 5.2, 7.6, Hβ), 2.31 (1H, dd, 5.2, 7.6, Hα)46.41.63 (1H, dd, 5.2, 7.6, Hβ), 2.31 (1H, dd, 5.2, 7.6, Hα)1671.94.46 (1H, ddd, 5.0, 7.6, 7.8)72.34.43 (1H, ddd, 5.2, 7.6, 7.9)72.34.43 (1H, ddd, 5.2, 7.6, 7.9)1756.01.62 (1H, dd, 7.7, 12.2)56.01.64 (1H, dd, 7.9, 12.4)56.01.64 (1H, dd, 7.9, 12.4)1816.21.18 (3H, s)16.11.20 (3H, s)16.11.20 (3H, s)1924.90.20 (1H, d, 4.5, Hα) 0.85 (1H, d, 4.5, Hβ)24.70.18 (1H, d, 4.6, Hα), 0.87 (1H, d, 4.6, Hβ)24.70.18 (1H, d, 4.6, Hα), 0.87 (1H, d, 4.6, Hβ)2029.71.72 (1H, m)28.51.95 (1H, m)28.51.91 (1H, m)2117.00.97 (1H, d, 7.6)17.20.97 (1H, d, 7.6)17.20.97 (1H, d, 7.6)2232.92.78 (1H, m, Hα), 2.86 (1H, m, Hβ)32.41.22 (1H, m, Hα), 1.81 (1H, m, Hβ)32.41.82 (1H, m, Hα), 1.01 (1H, m, Hβ)2329.51.21 (1H, m, Hα), 1.97 (1H, m, Hβ)30.31.42 (1H, m, Hα), 1.62 (1H, m, Hβ)31.32.12 (1H, m, Hα), 1.12 (1H, m, Hβ)24218.1/77.03.36 (1H, dd, 5.1, 12.0)79.53.46 (1H, dd, 5.1, 12.0)2576.5/71.9/71.9/2625.41.32 (3H, s)25.41.32 (3H, s)25.41.32 (3H, s)2724.81.00 (3H, s)24.01.18 (3H, s)24.51.18 (3H, s)2824.91.00 (3H, s)24.91.00 (3H, s)24.91.00 (3H, s)2912.20.82 (3H, s)12.80.82 (3H, s)12.80.82 (3H, s)3018.50.96 (3H, s)18.50.94 (3H, s)18.50.94 (3H, s)1'102.64.36 (1H, d, 7.8)102.64.35 (1H, d, 7.7)102.54.35 (1H, d, 7.7)2'73.93.18 (1H, dd, 7.8, 8.8)73.93.18 (1H, dd, 7.7, 8.7)73.93.18 (1H, dd, 7.7, 8.7)3'76.93.37 (1H, dd, 8.5, 8.8)76.93.40 (1H, dd, 8.7, 9.0)76.93.40 (1H, dd, 8.7, 9.0)4'70.23.28 (1H, dd, 8.5, 9.0)70.23.27 (1H, dd, 9.0, 9.2)70.23.27 (1H, dd, 9.0, 9.2)5'73.73.48 (1H, m)73.73.48 (1H, m)73.73.48 (1H, m)6'63.94.11 (1H, dd, 2.1, 11.9), 4.48 (1H, dd, 2.1, 11.9)63.94.11 (1H, dd, 2.0, 12.0), 4.48 (1H, dd, 2.0, 12)63.94.11 (1H, dd, 2.0, 12.0), 4.48 (1H, dd, 2.0, 12)

HOP~2~ was obtained as a white powder. \[α\]D~23~ = + 34.2 (CH~3~OH, *c* = 0.487 × 10^−2^); IR (NaCl) ν~max~ (cm^−1^): 3450 (OH), 1250 (C-O), 1713 (C = O). ^1^H and ^13^C data, see Table [2](#Tab2){ref-type="table"}.

HOP~3~ was obtained as a white powder. \[α\]D~23~ = + 20.2 (CH~3~OH, *c* = 0.458 × 10^−2^); IR (NaCl) ν~max~ (cm^−1^): 3477 (OH), 1249 (C-O), 1718 (C = O). ^1^H and ^13^C data, see Table [2](#Tab2){ref-type="table"}.

Effect of the mixture and isolated cycloartanes on formalin-induced pain in mice {#Sec15}
--------------------------------------------------------------------------------

Treatment with different doses of the mixture of cycloartanes significantly reduced the pain behavior during the first and the second phases of pain induced by formalin as compared to the control group. The percentages of inhibition ranged from 51.33 to 65.15 % for the first phase (Fig. [3a](#Fig3){ref-type="fig"}) and from 45.15 to 61.42 % for the second phase (Fig. [3b](#Fig3){ref-type="fig"}). The highest percentages of inhibition were obtained at 5 mg/kg during the first phase and 20 mg/kg in the second. Concordantly, systemic oral administration of the three main compounds (OP~3~, OP~5~ and OP~6~) significantly (*p* \<0.001) reduced the licking time of the paw during the first phase. No significant difference was observed between the effect of mixture and the individual compounds (Fig. [3c](#Fig3){ref-type="fig"}). OP~5~ reduced pain behavior by about 13 % during the second phase but this effect missed significance (*p* \> 0.05), while OP~3~ and OP~6~ exhibited significant analgesic effect similar to that of diclofenac (Fig. [3d](#Fig3){ref-type="fig"}).Fig. 3Effect of mixed (OPM) and isolated (pallidioside A: OP~3~, pallidioside B: OP~5~ and pallidioside C: OP~6~) cycloartanes on the first (panels **a** and **c**) and second (panels **b** and **d**) phases of formalin-induced pain in mice. Each bar represents the mean ± SEM, *n* = 6. *\*P \< 0.05*, *\*\*p \< 0.01*, *\*\*\*p \< 0.001* significant difference as compared to control group. Diclo: diclofenac

Effect of OP~3~, its aglycone (AOP~1~) and acetylated (HOP~1~) derivatives on formalin-induced pain in mice {#Sec16}
-----------------------------------------------------------------------------------------------------------

As shown in Fig. [4](#Fig4){ref-type="fig"}, oral administration of OP~3~ and its derivatives exhibited an effective analgesic effect on both phases of pain. There was no significant difference between the effect of OP~3~ and its derivatives during the first phase (Fig. [4a](#Fig4){ref-type="fig"}). At the second phase OP~3~ and derivatives also showed a significant analgesic effect but a significant difference was observed between the effect of the two OP~3~ derivatives, the aglycone AOP~1~ being significantly (*p* \<0.05) more active than the acetylated HOP~1~ (Fig. [4b](#Fig4){ref-type="fig"}).Fig. 4Effect of pallidioside A (OP~3~), its aglycone (AOP~1~) and acetylated (HOP~1~) derivatives on the first (panel **a**) and second (panel **b**) phases of formalin-induced pain in mice. Each bar represents the mean ± SEM of six animals. *\*p \< 0.05, \*\*p \< 0.01, \*\*\*p \< 0.001* significant different compared to the control. ^*α*^ *p \< 0.05* significant difference between the two groups*.* Diclo: diclofenac

Effect of OP~5~, its aglycone (AOP~2~) and acetylated (HOP~2~) derivatives on formalin-induced pain in mice {#Sec17}
-----------------------------------------------------------------------------------------------------------

Although OP~5~ and its derivatives all induced a significant analgesic effect on the first phase of pain induced by intraplantar administration of formalin, the acetylated derivative was significantly less potent than OP~5~ and its aglycone (Fig. [5a](#Fig5){ref-type="fig"}). On the second phase, OP~5~ and its acetylated derivative did not show significant analgesic effect as compared to control but AOP~2~ was significantly active as compared both to the control and HOP~2~ treated groups (Fig. [5b](#Fig5){ref-type="fig"}).Fig. 5Effect of pallidioside B (OP~5~), its aglycone (AOP~2~) and acetylated (HOP~2~) derivatives on the first (panel **a**) and second (panel **b**) phases of formalin-induced pain in mice. Each bar represents the mean ± SEM, *n* = 6. *\*\*P \<0.01*, *\*\*\*p \<0.001* significant difference compared to control. ^*α*^ *p \< 0.05* significant difference between the two groups*.* Diclo: diclofenac

Effect of OP~6,~ its aglycone (AOP~3~) and acetylated (HOP~3~) derivatives on formalin-induced pain in mice {#Sec18}
-----------------------------------------------------------------------------------------------------------

OP~6~ and its two derivatives exhibited significant analgesic effect on the first phase of pain induced by formalin. Meanwhile, OP~6~ proved to be more effective than any of its derivatives (Fig. [6a](#Fig6){ref-type="fig"}). This was more marked at the second phase were AOP~3~ and HOP~3~ lacked significant activity. However, OP~6~ was significantly active as compared both to the control group and the HOP~3~ treated group (Fig. [6b](#Fig6){ref-type="fig"}).Fig. 6Effect of pallidioside C (OP~6~), its aglycone (AOP~3~) and acetylated (HOP~3~) derivatives on the first (panel **a**) and second (panel **b**) phases of formalin-induced pain in mice. Each bar represents the mean ± SEM, *n* = 6. *\*\*\*p \<0.001* significant differences compared to the control. ^*α*^ *p \< 0.05* significant difference between the two groups. Diclo: diclofenac

Effect of OP~5~ and OP~6~ on mechanical hyperalgesia and inflammation induced by formalin in rats {#Sec19}
-------------------------------------------------------------------------------------------------

Systemic oral administration of OP~5~ and OP~6~ one hour before induction of pain both produced significant inhibition of hyperalgesia for up to 24 h. The acute maximal effect was observed 8 h post induction with OP~6~ at the dose of 5 mg/kg as compared to the negative control (Fig. [7a](#Fig7){ref-type="fig"}). This effect was similar to that of diclofenac at the same dose. During the 10 days treatment, OP~5~ at both doses shows significant effect only at the first day (Fig. [7b](#Fig7){ref-type="fig"}).Fig. 7Time-dependant acute (panel **a**) effect of Pallidioside B (OP~5~) and Pallidioside C (OP~6~) and repeated treatment of OP~5~ (panel **b**) on mechanical pain induced by Randal sellito in rat paw injected with formalin (2 %, 100 μl). Animals were orally treated with different compounds and injected one hour later in the paw with formalin. Pain threshold was measured before treatment and after formalin injection. For chronic experiment, animals were daily treated and pain threshold was measured before drug administration. Each point represents the mean ± SEM, *n* = 8. *\*P \< 0.05, \*\*p \< 0.01, \*\*\*p \< 0.001* significant differences compared to the control. Diclo: diclofenac

As shown in Fig. [8](#Fig8){ref-type="fig"}, OP~6~ instead increase the inflammation induced by formalin. The inflammation was significantly reduced by OP~5~ at the dose of 5 mg/kg at the third hour post induction. Repeated administration of OP~5~ at both doses did not show any anti-inflammatory activity all along the 10 days of experiment.Fig. 8Time-dependant acute (panel **a**) effect of Pallidioside B (OP~5~) and Pallidioside C (OP~6~) and repeated treatment of OP~5~ (panel **b**) on inflammation induced by formalin (2 %, 100 μl) injection in rat paw. Animals were orally treated with different compounds and injected one hour later with formalin. The diameter of the paw was measured before treatment and after formalin injection. For chronic experiment, animals were daily treated and the diameter of the paw was measured before drug administration. Each point represents the mean ± SEM, *n* = 8. *\*P \< 0.05, \*\*p \< 0.01, \*\*\*p \< 0.001* significant differences compared to the control. Diclo: diclofenac

Biochemical analyses {#Sec20}
--------------------

Results of the assays of oxidative stress parameters are presented in Table [3](#Tab3){ref-type="table"}. After 10 days of repeated treatment, OP~5~ significantly reduced the malondialdehyde production and increased the superoxide dismutase activity in the liver, but has no effect on these parameters in the kidney. OP~5~ did not affect the concentration of NO, glutathione and the activity of catalase both in the liver and kidneys. The concentration of ALAT dose-dependently increased in the serum of OP~5~ treated animals as compared to the control group. Meanwhile, the effect was not statistically significant.Table 3Effects of different treatments on the biochemical parameters of oxidative stress and hepatotoxicityParametersTissueControlDiclofenac (5 mg/kg)OP5 (2.5 mg/kg)OP5 (5 mg/kg)NO (μmol/g tissue)liver0.49 ± 0.060.28 ± 0.06\*0.48 ± 0.040.36 ± 0.03kidney1.014 ± 0.110.66 ± 0.151.23 ± 0.150.85 ± 0.06Glutathione (μmol/g tissue)liver0.12 ± 0.010.11 ± 0.010.12 ± 0.010.10 ± 0.01kidney0.07 ± 0.010.04 ± 0.010.09 ± 0.010.07 ± 0.00MDA (μmol/g tissue)liver9.37 ± 0.749.80 ± 0.463.10 ± 0.37\*\*\*9.42 ± 0.24kidney0.12 ± 0.010.09 ± 0.020.14 ± 0.010.12 ± 0.00SOD (U/mg protein)liver0.05 ± 0.010.12 ± 0.00\*0.08 ± 0.020.11 ± 0.01\*kidney0.19 ± 0.080.12 ± 0.050.09 ± 0.020.10 ± 0.04Catalase (U/mg protein)kidney0.08 ± 0.010.08 ± 0.010.10 ± 0.020.08 ± 0.01ALAT (U/mg protein)serum0.39 ± 0.150.4 ± 0.010.60 ± 0.080.80 ± 0.21ASAT (U/mg protein)serum1.28 ± 0.101.58 ± 0.131.35 ± 0.071.313 ± 0.11Each value represents the average ± ESM of eight animals.^\*^ *p* \< 0.05, ^\*\*\*^ *p* \< 0.001 significant difference compared to the control group

Ulcerogenic activity {#Sec21}
--------------------

It is observed from Table [4](#Tab4){ref-type="table"} that after 10 days treatment, animals treated with OP~5~ at both doses showed no ulceration in their gastric mucosa. Ulceration was recorded in all animal treated with diclofenac with a percentage ulcerated surface of 15.95 %. It was also observed that repeated administration of diclofenac at the dose of 5 mg/kg/day significantly reduced the mucus production, whereas OP~5~ has no effect.Table 4Evaluation of the ulcerogenic activity of Diclofenac (Diclo) and OP~5~GroupsDoses (mg/kg)Mucus weight (mg)Total surface of stomach (mm^2^)ulcerated surface (mm^2^)% of ulcerated animalsControl0.163 ± 0.0131479.00 ± 72.790.00 ± 0.000Diclo50.073 ± 0.014\*1406.00 ± 78.92221.10 ± 0.00\*\*\*100OP52,50.127 ± 0.0181886.00 ± 127.000.00 ± 0.000OP550.090 ± 0.0091723.00 ± 46.900.00 ± 0.000Each value represents the mean ± SEM of eight animals.\**p* \< 0.05, \*\*\**p* \< 0.001 significant difference compared to the control group. *Diclo* diclofenac

Discussion {#Sec22}
==========

This work was undertaken to evaluate the analgesic and anti-inflammatory effects of three cycloartanes isolated from *Oxyanthus pallidus* and their derivatives. The mixture of cycloartanes significantly inhibited both phases of pain induced by the injection of formalin. When tested individually, isolated compounds exhibited different intensities of activity. During the first phase of pain, the three compounds showed significant antinociceptive effect. No significant difference was observed between their effects although OP~5~ was nominally the most effective. Regarding the second phase of pain, OP~3~ and OP~6~ induced a significant analgesic effect while OP~5~ showed less activity. It is well known that formalin model which is consider mimicking clinical pain \[[@CR23]\], has two main distinct phases. The first one characterized as neurogenic pain is related to chemical stimulation of A~δ~ and C fibers, the release of excitatory amino-acids, nitric oxide and substance P while the second phase known as inflammatory pain is related to the release of bradykinin and prostaglandins \[[@CR16], [@CR24]\]. Drugs that inhibit only the first or both phases are considered as central analgesics while those acting only at the second phase are considered as peripheral analgesic drugs \[[@CR25]\]. The mixture of cycloartanes as well as OP~3~ and OP~6~ significantly inhibited both phases of formalin-induced pain while OP~5~ inhibited predominately the first phase. The activity of these compounds either taken individually or as a mixture was significantly more potent at the first phase than at the second. These results indicate that the tested cycloartanes may be central acting molecules. The structural difference between these compounds is at C-24, which in the case of OP~3~ carries a ketone while that of OP~5~ and OP~6~ carry a hydroxyl group. The combination of the structure and activity of molecules shows that the substitution on C-24 by the ketone group or the hydroxyl group does not significantly affect the analgesic activity in the formalin model. However, the analgesic activity on the inflammatory pain can be improved if the hydroxyl group at C-24 is placed in front of the plane.

Acid hydrolysis leading to aglycone did not affect the analgesic activity of different compounds on the neurogenic pain but significantly reduced the effect of OP~6~ on the inflammatory pain. These results suggest a probable interaction between the hydroxyl group and sugar, all placed in front of the plane, which could be necessary for the activity of OP~6~. This hypothesis is further supported by the results obtained after acetylating OP~3~, OP~5~ and OP~6~. In fact, the process has significantly inhibited the analgesic activity of all these compounds. We can then conclude that the hydroxyl groups attached to the aglycone are responsible for the analgesic activity of these cycloartanes, mainly as far as the inflammatory pain is concern. These results corroborate those previously obtained by Ayatollahi et al. \[[@CR12]\] who showed that cycloartanes can deactivate protein Kinase C, thanks to their hydroxyl group. In addition, it has been shown that PKC mediates the phase 2 of formalin-induced pain \[[@CR26]\]. Taking all together, it can be thought that cycloartanes from *Oxyanthus pallidus* induced their analgesic effect by inhibiting at least partially the activation of PKC.

OP~5~ and OP~6~ were further tested on mechanical hyperalgesia and inflammation induced by formalin in rats. In the acute test, they significantly reduced mechanical hyperalgesia from the first hour after induction of pain and lasted until the 24th hour post administration. OP~5~, in contrary of OP~6~, showed a significant anti-inflammatory effect only at the 3rd hour post treatment. These results indicate that the analgesic effects of tested cycloartanes are not dependent to their anti-inflammatory activity if any. Furthermore, repeated treatment with OP~5~ did not show any anti-inflammatory effect, demonstrating that OP~5~ is devoid of anti-inflammatory effect.

It was observed that unlike diclofenac, repeated oral administration of OP~5~ did not induce gastric ulceration and did not significantly affect the gastric mucus weight. Diclofenac reduces mucus production and induces gastric ulcer through the reduction of prostaglandin resulting from its inhibitory effect on cyclooxygenase. The above result suggests that OP~5~ do not inhibit cyclooxygenase.

The strong involvement of oxidative stress in inflammatory and painful phenomena \[[@CR27], [@CR28]\] has motivated the study of the in vivo antioxidant activity of OP~5~ in animals treated chronically. OP~5~ significantly reduced malondialdehyde (MDA) and increased the level of superoxide dismutase (SOD) without affecting the activity of catalase and nitric oxide amount. These results suggest that OP~5~ might potentiate the in vivo antioxidant capacity of the organism by increasing the SOD activity that could lead to reduction of lipid peroxydation. In other to evaluate the impact of OP~5~ on the liver integrity, alanine aminotrasferase (ALAT) and aspartate aminotrasferase (ASAT) activities were assayed in the serum. A dose dependent increase in ALAT was observed in OP~5~ treated group, although not significant. It is well known that plasma increase in ALAT and ASAT, especially ALAT is a result of liver cells necrosis. Thus, even though there was no evidence of hepatotoxic effect, caution should be taken when using OP~5~.

Conclusion {#Sec23}
==========

Cycloartanes isolated from *Oxyanthus pallidus* possess analgesic effects that are dissociated from anti-inflammatory activity if any. The analgesic effect of these compounds especially the effect on inflammatory pain may be due to the presence of hydroxyl group in front of the plane. Meanwhile, these cycloartanes are more potent on the neurogenic than on the inflammatory pain.
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